EU
ESPR

Emory University’s Esperion Therapeutics ESPR Stock Holding History

Emory University’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-33,975
Closed -$1.7M – 47
2017
Q3 		$1.7M Sell
33,975
-12,791
-27% -$617K 1.35% 31
2017
Q2 		$2.16M Buy
+46,766
New +$1.72M 1.91% 3

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Emory University's ESPR Position: Q4 2017 in Review

Emory University sold out of Esperion Therapeutics (ESPR) in Q4 2017, closing a stake of 33,975 shares — an estimated $1.7M sold.

Emory University first reported a position in ESPR in Q2 2017 and held it in 2 quarters. The position peaked at $2.16M in Q2 2017. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2017.

  • Emory University reported no remaining Esperion Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Emory University sold 33,975 Esperion Therapeutics shares in Q4 2017, an estimated $1.7M.
  • Emory University first reported a position in Esperion Therapeutics in Q2 2017 and held it in 2 quarters.
  • Emory University's Esperion Therapeutics position peaked at $2.16M in Q2 2017.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2017.

Based on Emory University's 13F filing for Q4 2017, filed 13 Feb 2018.